Background: There is a need for a simple and efficacious treatment for cutaneous leishmaniasis with an acceptable side-effect profile.
Methods: We conducted a randomized, vehicle-controlled phase 3 trial of topical treatments containing 15% paromomycin, with and without 0.5% gentamicin, for cutaneous leishmaniasis caused by Leishmania major in Tunisia.